Haleon: Berenberg initiates coverage as a buyer

(CercleFinance.com) - Berenberg announced on Wednesday that it has begun to monitor Haleon shares with a buy rating and a target price of 407 pence.


The analyst underpins his optimism with the US launch of Eroxon, a topical gel for male erectile dysfunction, which he believes should enable the group to post organic growth of 5.8% in 2025, compared with the current consensus target of 4.9%.

He also highlights Haleon's exposure to dynamic market segments, where the Group should generate growth of 4.6% in the medium term, above the 4.1% average expected for the sector.

Finally, the broker points out that the share is currently trading at a 17% discount to other major manufacturers of household and personal care products.

At current prices, its target price gives the stock around 25% upside potential.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.